Billets de Michelle Dawson

Billet publié sur Twitter/X le 08/03/2021 10:52

Twitter/X Publication avec DOI crossref Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Thomas W. Frazier, Daniel L. Coury, Kristin Sohl, Kayla E. Wagner, Richard Uhlig, Steven D. Hicks, Frank A. Middleton (2021). Evidence‐based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism. Autism Research, 14(6), 1271-1283. Wiley.

Date de publication
08/03/2021
Identifiant
10.1002/aur.2498
Auteurs
Thomas W. Frazier, Daniel L. Coury, Kristin Sohl, Kayla E. Wagner, Richard Uhlig, Steven D. Hicks, Frank A. Middleton
Source
Autism Research
Détails
14(6), 1271-1283
Type de référence
article
Éditeur
Wiley
Source de métadonnées
crossref

Résumé

Abstract Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence‐based interventions at an early age when treatments are most effective. The present study shows how implementing a second‐order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye‐tracking technology, both scalable and easy‐to‐implement biomarkers recently introduced in ASD research. Results of the current cost‐savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. Lay Summary This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan.

Auteur·ices de l’étude dans cette référence citée